# The Pharmalot is back for another week of fun and games.

*biotech · news · 2026-05-01 · STAT*

## Key points

- The FDA has proposed excluding semaglutide and tirzepatide from the bulk compounding list.
- This move blocks large compounding pharmacies from making versions of Wegovy, Ozempic, Mounjaro, and Zepbound.
- The FDA determined there is no 'clinical need' for compounded semaglutide or tirzepatide products.
- This decision is considered a victory for Novo Nordisk and Eli Lilly, the drugs' manufacturers.

**Companies:** Eli Lilly, Novo Nordisk
**Countries:** United States

[Read the full story on STAT](https://www.statnews.com/pharmalot/2026/05/01/obesity-drugs-excluded-from-compounding-list-astrazeneca-setback/)

---

Canonical: https://newsio.io/n/561efb67-8c61-4461-ab55-ec70c2f9292d/the-pharmalot-is-back-for-another-week-of-fun-and-games-this-weeks-agenda-includ
Summarized by Newsio from STAT. https://newsio.io/how-it-works